Ray Kemper

Ray Kemper is the current Vice President of Pharmaceutical Development at Nuvalent. Prior to this, they held various positions at Vertex Pharmaceuticals, Merck, Roche, and Boehringer Ingelheim Pharmaceuticals. Ray began their career as a Postdoctoral Research Associate at the University of Wisconsin-Madison in 1995. In 1999, they became a Sr Research Toxicologist at DuPont Haskell Laboratories. In 2005, they moved to Boehringer Ingelheim Pharmaceuticals where they became a Sr Principal Scientist. In 2011, they left Boehringer Ingelheim to join Roche as a Research Leader and Group Head of Mechanistic Toxicology in the US. Ray left Roche in 2013 to return to Vertex Pharmaceuticals as their Director of Discovery and Investigative Toxicology. Ray remained in this role until 2021 when they were promoted to Vice President of Pharmaceutical Development at Nuvalent.

Ray Kemper holds a PhD in Pharmacology and Toxicology from the University of Louisville School of Medicine, as well as a Bachelor of Arts in Chemistry from the same institution.

Their manager is Christopher Turner, Chief Medical Officer. They are on a team with Viola Zhu - Medical Director, Ruth Adams - VP, Clinical Operations, and Benjamin Lane - VP, Pharmaceutical Development.